doi:10.1016/S0140-6736(23)01053-X PubMed: This trial evaluated retatrutide in 281 participants with type 2 diabetes, showing up to 16.94% weight loss and significant HbA1c reductions with favorable safety profile comparable to other GLP-1 based therapies
And I guess a particular, I guess, interesting point for Australia is that currently, Ozempic's not approved by the PBS, so it means people have to pay full price for these drugs
The participants were overweight or obese and had cardiovascular disease but no history of diabetes
Because they do not overlap, some patients see an added benefit when the two are combined
Some prescribers use different concentrations, which changes the unit calculations entirely
Semaglutide has been the subject of various studies highlighting its efficacy in promoting weight reduction